Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $2.56, $0.41 better than the analyst estimate of $2.15. Revenue for the quarter came in at $7.14 billion versus the consensus estimate of $6.35 billion.

GUIDANCE:

Gilead Sciences sees FY2017 revenue of $24-25.5 billion, versus the consensus of $24.8 billion.

Revised Full Year 2017 Guidance

Gilead revised its full year 2017 guidance, initially provided on February 7, 2017:

(In millions, except percentages and per share amounts)		Initially Provided February 7, 2017 Reiterated May 2, 2017		Updated July 26, 2017
Net Product Sales		$22,500 - $24,500		$24,000 - $25,500
Non-HCV Product Sales		$15,000 - $15,500		$15,500 - $16,000
HCV Product Sales		$7,500 - $9,000		$8,500 - $9,500
Non-GAAP*
Product Gross Margin		86% - 88%		86% - 88%
R&D Expenses		$3,100 - $3,400		$3,200 - $3,400
SG&A Expenses		$3,100 - $3,400		$3,200 - $3,400
Effective Tax Rate		25.0% - 28.0%		25.0% - 28.0%
Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses		$0.84 - $0.91		$0.86 - $0.93

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.